Sociedad Americana de Hirudoterapia

Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation

Research article published in Journal of biological chemistry (1987)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportDesarrollo de fármacosTuszynski GP et al. · Journal of biological chemistry, 1987

Abstract

The purpose of this study was to purify and characterize the agent responsible for the antimetastatic activity of an extract of the salivary glands (SGE) of the Mexican leech Haementeria officinalis. When administered intravenously in mice on the same day as the intravenous inoculation of T241 sarcoma cells, SGE markedly reduces the number and size of lung tumor colonies. In designing a purification protocol for the antimetastatic agent, we postulated that the antimetastatic agent would also display anticoagulant activity. Thus, we discovered that heparin affinity chromatography followed by anion-exchange chromatography results in a fraction highly enriched in both potent anticoagulant activity and potent antimetastatic activity. Approximately, 200-300 micrograms of purified protein is isolated from 150 mg of SGE. As little as 15 micrograms of this material inhibits tumor cell metastasis to the same extent as 1.0 mg of the unfractionated SGE. When analyzed on sodium dodecyl sulfate gels the active fraction consists mainly of one polypeptide band having an apparent molecular weight of approximately 17,000 under either reducing or nonreducing conditions. The protein has a pI of approximately 9.5 and a molecular weight of approximately 17,000 under nondenaturing conditions. A specific antiserum prepared against the 17,000-dalton protein indicated that this protein is the major anticoagulant and antimetastatic agent of leech salivary gland extract. We have termed this anticoagulant, antimetastatic agent "antistasin." We hypothesize that antistatin inhibits coagulation via factor Xa, and not thrombin, since factor Xa, but not thrombin, is rapidly inactivated upon addition of antistasin. The mechanism of antistasin's antimetastatic activity is currently under investigation.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.S.
Indexed MeSH termsAmino AcidsAnimalsBlood CoagulationBlood Coagulation TestsChromatography, AffinityFactor XFactor XaHumansInvertebrate HormonesLeechesMiceMolecular Weight

Resumen

Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation.

Por qué esto importa para la hirudoterapia

This study purified the antimetastatic agent from salivary gland extracts of the Mexican leech Haementeria officinalis, finding that a ~17,000-Da protein (pI ~9.5) accounts for both the extract's anticoagulant and antimetastatic activity. Intravenous administration of this protein in mice reduced lung tumor colonies from T241 sarcoma cells, and it inactivated factor Xa but not thrombin; the authors termed it 'antistasin.' For ASH's domain, this is relevant as it characterizes a leech-derived secretome molecule with dual anticoagulant and antimetastatic properties. CAVEAT: This is a preclinical/biochemical study with animal tumor data and in-vitro coagulation assays; the abstract appears to contain a typographical inconsistency ('antistatin' vs 'antistasin'), and the work concerns a purified Haementeria protein rather than whole-organism hirudotherapy.

Citación

Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation

Tuszynski GP et al. · Journal of biological chemistry, 1987

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.